Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

SABCS 2009

9 - 13 Sep 2009
Bisphosphonates for breast cancer patients
Prof Michael Gnant - Medical University of Vienna, Austria
Bisphosphonates for breast cancer patients ( Prof Michael Gnant - Medical University of Vienna, Austria )
9 Feb 2010
Typical course for receptor positive early breast cancer
Dr Kimberly Blackwell - Duke University Medical Centre, USA
Typical course for receptor positive early breast cancer ( Dr Kimberly Blackwell - Duke University Medical Centre, USA )
9 Feb 2010
Oral bisphosphonate and breast cancer: prospective results from the Women's Heal...
Dr Rowan Chlebowski - Harbor-University of California, Los Angeles
Oral bisphosphonate and breast cancer: prospective results from the Women's Health Initiative (WHI) ( Dr Rowan Chlebowski - Harbor-University of California, Los Angeles )
28 Jan 2010
Use of bisphosphonates and risk of postmenopausal breast cancer
Dr Gad Rennert - Technion-Israel Institute of Technology, Israel
Use of bisphosphonates and risk of postmenopausal breast cancer ( Dr Gad Rennert - Technion-Israel Institute of Technology, Israel )
28 Jan 2010
Denosumab versus zoledronic acid for skeletal-related events in breast cancer pa...
Dr Alison Stopeck - University of Arizona Cancer Center
Denosumab versus zoledronic acid for skeletal-related events in breast cancer patients with bone metastases ( Dr Alison Stopeck - University of Arizona Cancer Center )
28 Jan 2010
Short term biological effects of the combination of letrozole and zoledronic aci...
Prof Nigel Bundred - University of Manchester, UK
Short term biological effects of the combination of letrozole and zoledronic acid on invasive breast cancer ( Prof Nigel Bundred - University of Manchester, UK )
28 Jan 2010
Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase ...
Prof Jenny Chang - Baylor College of Medicine, USA
Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase inhibitors ( Prof Jenny Chang - Baylor College of Medicine, USA )
28 Jan 2010
Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor-pos...
Dr Angelo Di Leo - Hospital of Prato, Italy
Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor-positive advanced breast cancer ( Dr Angelo Di Leo - Hospital of Prato, Italy )
28 Jan 2010
Sorafenib in combination with paclitaxel for locally recurrent or metastatic bre...
Prof William Gradishar - Robert H. Lurie Comprehensive Cancer Center, USA
Sorafenib in combination with paclitaxel for locally recurrent or metastatic breast cancer ( Prof William Gradishar - Robert H. Lurie Comprehensive Cancer Center, USA )
28 Jan 2010
A novel strategy in treating endocrine resistance using combination therapy
Dr Rajeshwar Rao Tekmal - University of Texas Health Science Center, San Antonio...
A novel strategy in treating endocrine resistance using combination therapy ( Dr Rajeshwar Rao Tekmal - University of Texas Health Science Center, San Antonio, USA )
28 Jan 2010
Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast c...
Dr Kimberly Blackwell - Duke University Medical Center, USA
Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast cancer ( Dr Kimberly Blackwell - Duke University Medical Center, USA )
28 Jan 2010
Bevacizumab in combination with chemotherapy for second-line treatment of HER2-n...
Prof Adam Brufsky - University of Pittsburgh Cancer Institute, USA
Bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer ( Prof Adam Brufsky - University of Pittsburgh Cancer Institute, USA )
28 Jan 2010
Bevacizumab plus docetaxel compared with placebo plus docetaxel for locally recu...
Dr David Miles - Mount Vernon Hospital, United Kingdom
Bevacizumab plus docetaxel compared with placebo plus docetaxel for locally recurrent or metastatic breast cancer ( Dr David Miles - Mount Vernon Hospital, United Kingdom )
28 Jan 2010
Exemestane vs tamoxifen followed by exemestane
Dr Daniel Rea - University of Birmingham, UK
Exemestane vs tamoxifen followed by exemestane ( Dr Daniel Rea - University of Birmingham, UK )
28 Jan 2010
Using biology of tumours to predict effective therapies
Dr Laura Van`t Veer - The Netherlands Cancer Institute, Amsterdam, The Netherlan...
Using biology of tumours to predict effective therapies ( Dr Laura Van`t Veer - The Netherlands Cancer Institute, Amsterdam, The Netherlands )
27 Jan 2010
Translation of endocrine systemic treatment
Prof Giuseppe Viale - European Institute of Oncology, Milan, Italy
Translation of endocrine systemic treatment ( Prof Giuseppe Viale - European Institute of Oncology, Milan, Italy )
27 Jan 2010
New paradigms in tumour immunotherapy
Dr Tyler Curiel - University of Texas Health Science Center, San Antonio, USA
New paradigms in tumour immunotherapy ( Dr Tyler Curiel - University of Texas Health Science Center, San Antonio, USA )
27 Jan 2010
Early breast cancer trials
Prof Sarah Darby - Clinical Trial Service Unit, Oxford University, UK
Early breast cancer trials ( Prof Sarah Darby - Clinical Trial Service Unit, Oxford University, UK )
27 Jan 2010
Causes and prevention of breast cancer
Dr Valerie Beral - University of Oxford, UK
Causes and prevention of breast cancer ( Dr Valerie Beral - University of Oxford, UK )
27 Jan 2010
Applying new proteomic technologies to improve patient management
Dr Gordon Mills - University of Texas MD Anderson Cancer Center, Houston, USA
Applying new proteomic technologies to improve patient management ( Dr Gordon Mills - University of Texas MD Anderson Cancer Center, Houston, USA )
27 Jan 2010
Sentinel lymph node biopsy
Prof Quentin Pankhurst and Dr Michael Douek - University College London, UK
Sentinel lymph node biopsy ( Prof Quentin Pankhurst and Dr Michael Douek - University College London, UK )
27 Jan 2010
Fulvestrant as treatment for advanced breast cancer
Dr Angelo Di Leo - Sandro Pitigliani Medical Oncology Unit, Prato Hospital, Ital...
Fulvestrant as treatment for advanced breast cancer ( Dr Angelo Di Leo - Sandro Pitigliani Medical Oncology Unit, Prato Hospital, Italy )
27 Jan 2010
How life style factors effect survival of breast cancer patients
Prof Michelle Holmes - Harvard Medical School, USA
How life style factors effect survival of breast cancer patients ( Prof Michelle Holmes - Harvard Medical School, USA )
27 Jan 2010
Evaluating strategies for endocrine therapy
Dr Meredith Regan - Dana-Farber Cancer Institute, Boston, USA
Evaluating strategies for endocrine therapy ( Dr Meredith Regan - Dana-Farber Cancer Institute, Boston, USA )
27 Jan 2010
Emerging approaches to clinical trial design
Susan Hilsenbeck - Baylor College of Medicine, Houston, USA
Emerging approaches to clinical trial design ( Susan Hilsenbeck - Baylor College of Medicine, Houston, USA )
27 Jan 2010
Cancer and the bone micro-environment
Prof Theresa Guise - Indiana University School of Medicine, USA
Cancer and the bone micro-environment ( Prof Theresa Guise - Indiana University School of Medicine, USA )
27 Jan 2010
Optimal way to use herceptin with adjuvant therapy
Prof Edith Perez - Mayo Clinic, Florida, USA
Optimal way to use herceptin with adjuvant therapy ( Prof Edith Perez - Mayo Clinic, Florida, USA )
27 Jan 2010
San Antonio Breast Cancer Symposium, 9th-13th December 2009
Prof Gordon McVie - European Institute of Oncology, Milan
San Antonio Breast Cancer Symposium, 9th-13th December 2009 ( Prof Gordon McVie - European Institute of Oncology, Milan )
13 Jan 2010